Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study

• Tadao Akizawa ,

  Roles Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: akizawa@med.showa-u.ac.jp

  Affiliation Division of Nephrology, Department of Medicine, Showa University School of Medicine, Namics 301, Takanawa, Minato-ku, Tokyo, Japan

  ⨯
• Ryutaro Shimazaki,

  Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing

  Affiliation R&D Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan

  ⨯
• Masafumi Fukagawa,

  Roles Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

  Affiliation Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan

  ⨯
• Evocalcet Study Group

  ¶Complete membership of authors is noted in the Acknowledgments

  ⨯